Lupin Ltd.

LUPIN

₹1981.3

3.66% (70.0)

Market Cap

₹90,516 Cr.

P/E

24.47

Key Ratios

Edit Ratio's

Market cap

90,516 Cr

24.47

Prom Holding

46.90 %

ROE (%)

19.08

ROCE (%)

21.89

Div Yield (%)

0.61

Sales

23,375 Cr

OPM (%)

24.58 %

Debt to Equity

0.30

Edit Ratio's

About

Lupin is a leading global pharmaceutical company based in Mumbai, India, specializing in brand… Read more

Low

1795

52W Range

High

2403

Timeline

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statementNew

Edit rows

Forensics

12 Yes

Positive for this company

1 Neutral

Neutral for this company

4 No

Negative for this company

0 No Data

Insufficient data to analyse

Accounting & Shareholding

Contingent Liabilities

Company does not have significant contingent liabilities
Depreciation Effect

Depreciation accounting is not leading to increase in profits
Other Income

Other income is not affecting ratios of the company
Pledge

Promoters have not pledged a significant portion of their holding
Retail Holding

Retail has been selling the stock which is usually a good time to buy
Revenue Recognition

Company is converting accounting profit to cash
Promoter Holding

Promoter has not sold any shares in the last 90 days

Price & Performance

Capex vs ROCE

Roce of the company has increased over the last three years
ROE

Net profit margin is responsible for roe increase over last 10 years
Share price

Share price has increased over last 10 years due to earnings
Working Capital

Working capital of the company seems to be under control
Debt

Company should not have issues servicing its debt
Balance Sheet Strength

Balance sheet of the company is strong. it shouldnt have solvency or liquidity issues
Current vs Historic Valuation

Company is trading at a premium to 3yr historic valuations
Sales Growth

Sales of the company has grown at a slow pace
Margin Stability

Margins of the company are volatile
ROCE Strength

Roce of the company is not consistently strong

Market Share

8 %

(as of Mar 25)

Historic

Anti - Diabetes - Market Share

3.08 %

(as of Jul 22)

Historic

Anti-Infectives - Market Share

0.03 %

(as of May 19)

Historic

Anti-Malarial - Market Share

0.09 %

(as of Nov 21)

Historic

Antineo Plastic - Market Share

2.15 %

(as of Nov 21)

Historic

Blood Related - Market Share

6.10 %

(as of Mar 25)

Historic

Cardiovascular - Market Share

0.24 %

(as of Nov 21)

Historic

Dermatology - Market Share

0.48 %

(as of Nov 21)

Historic

Endocrinology - Market Share

2.70 %

(as of Mar 25)

Historic

Gastro-Intestinal - Market Share

3.60 %

(as of Mar 25)

Source/Historic

Gynecology - Market Share

2.70 %

(as of Mar 25)

Source/Historic

Neurological - Market Share

1.70 %

(as of Nov 21)

Historic

Ophthalmology - Market Share

2.06 %

(as of Nov 21)

Historic

Pain - Market Share

3.50 %

(as of Sep 24)

Historic

Pharmaceutical Sector - Market Share

6.20 %

(as of Mar 25)

Source/Historic

Respiratory - Market Share

0.46 %

(as of Jul 22)

Historic

Sex Stimulants - Market Share

0.23 %

(as of Nov 21)

Historic

Stomatological - Market Share

18.70 %

(as of Mar 21)

Source/Historic

Thyroid Hormone(Levothyroxine) - Market Share

3.39 %

(as of Nov 21)

Historic

Urology - Market Share

0 %

(as of Jul 22)

Historic

Vaccines - Market Share

1.49 %

(as of Jul 22)

Historic

Vitamin & Dietary Supplements - Market Share

Revenue mix

Product Wise Break-Up

Segment Break-Up

Therapeutic Area Wise Break-Up - Domestic

Location Wise Break-Up

Acute vs Chronic

Operational Metrics

Number of ANDA's Filed in USA (.)
Source
Number of ANDA's Approved By USFDA (.)
Source
Domestic Sales Growth - YoY (%)
Source
US DMF Filings (.)
Source
R&D as a % of Total Sales (%)
Source

Peer Comparison

Corporate Actions

Consolidated

DATE

DETAILS

Show Less

Suppliers

Bharat Dynamics Ltd.
Navin Fluorine International Ltd.
Neuland Laboratories Ltd.
Shaily Engineering Plastics Ltd.
Borosil Renewables Ltd.
GMM Pfaudler Ltd.
Aarti Drugs Ltd.
Kilitch Drugs (India) Ltd.
Hindusthan National Glass & Industries Ltd.
Vivimed Labs Ltd.

Showing 5 of 10

FAQs on Lupin Ltd. Business

What does Lupin do?

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in many markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health.

Who are the competitors of Lupin?

Lupin major competitors are Zydus Lifesciences, Mankind Pharma, Dr. Reddy's Lab, Alkem Laboratories, Aurobindo Pharma, Abbott India, Glenmark Pharma.
Market Cap of Lupin is ₹90,516 Crs.
While the median market cap of its peers are ₹65,284 Crs.

Is Lupin financially stable compared to its competitors?

Lupin seems to be less financially stable compared to its competitors.
Altman Z score of Lupin is 7.15 and is ranked 5 out of its 8 competitors.

View FAQ's On Shareprice

Global Leaders

Companies with a dominant global position in a product. Might be a sign of very strong moat.

Run Query

Company Filing

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release	May Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Sep Dec	Dec
Investor Presentation	May Aug	Mar Jun Sep Dec	Mar Jun Sep Dec	Jan Feb Mar May Jun Aug Sep Dec	Jan Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec		Mar Dec	Mar
Conference Call	Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Jun Sep Dec		Dec
Conference Call SummaryCon Call Summary Powered by Gemini

Discussions & Analysis

Lupin Ltd.

View the discussion on ValuePickr

Lupin - An Interesting Turnaround Story In Pharma Sector - Logical Investor

Pharmaceutical Sector

How The Pharma Industry Works - PPFAS

Deep Dive into Pharma Sector - Omkara Capital

Pharma Compliance In-Depth - Amit Rajan

Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar

Nutraceuticals- Industry Overview - Value Educator

GLP-1: The Drug Redefining Diabetes, Obesity, and Pharma’s Future - Perpetuity

Generic Opportunity for Indian Pharma Companies - Anish Moonka

Understanding the CDMO Sector - Will It Be The Next Megatrend - SOIC

Ideas Dashboard

Timeline

Watchlist

Portfolio

Alerts

Research

Stock Screener

Market

Raw Material

Lupin Ltd.

Lupin Ltd.

Key Ratios

About

Timeline

Company Timeline

12 Yes

1 Neutral

4 No

0 No Data

Accounting & Shareholding

Contingent Liabilities

Depreciation Effect

Other Income

Pledge

Retail Holding

Revenue Recognition

Promoter Holding

Price & Performance

Capex vs ROCE

ROE

Share price

Working Capital

Debt

Balance Sheet Strength

Current vs Historic Valuation

Sales Growth

Margin Stability

ROCE Strength

Product Wise Break-Up

UNLOCK PREMIUM

Segment Break-Up

UNLOCK PREMIUM

Therapeutic Area Wise Break-Up - Domestic

UNLOCK PREMIUM

Location Wise Break-Up

UNLOCK PREMIUM

Acute vs Chronic

UNLOCK PREMIUM

What does Lupin do?

Who are the competitors of Lupin?

Is Lupin financially stable compared to its competitors?

SIGN UP FOR FREE